ArticleTurkish journal of pharmaceutical sciences2026
Exploring the Role of Metabolites in Torsadogenic Risk Assessment: A Text-Mining Approach.
Article in Turkish journal of pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Torsades de pointes (TdP) is a life-threatening ventricular arrhythmia often caused by the inadvertent inhibition of the human ether-à-go-go-related gene (hERG). Conventional pre-market evaluations, which emphasize parent molecules, often yield inaccurate predictions due to the multifaceted nature of TdP. This study aimed to investigate the role of metabolites and their interplay with parent molecules in the manifestation of TdP. Materials and Methods: A literature-based text-mining approach was employed, using the adverse outcome pathway-helpFinder tool. The analysis scrutinized 64 selected active ingredients, categorized by their torsadogenic risks, to evaluate the distinct proarrhythmic contributions of their metabolites. Results: This text-mining exploration revealed qualitative evidence that metabolites variably modulate TdP vulnerability. Specifically, certain metabolites can independently exacerbate proarrhythmic profiles, whereas others do not inhibit hERG and therefore represent safer therapeutic alternatives than their parent molecules. Conclusion: Metabolites play a paramount role in altering the torsadogenic risk profile of pharmaceutical products. Incorporating comprehensive metabolite data into cardiac safety evaluations is essential for a more accurate risk assessment and should be considered in future pharmaceutical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.